A year in the life of German patients with COPD: the DACCORD observational study
Authors:
- David YoungDYDavid Young
- Roland BuhlRBRoland Buhl
Open Access
- 1 July 2016
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 11 (1) , 1639-1646
Abstract
A year in the life of German patients with COPD: the DACCORD observational study Roland Buhl,1 Carl-Peter Criée,2 Peter Kardos,3 Claus Vogelmeier,4,5 Nadine Lossi,6 Claudia Mailänder,6 Heinrich Worth7 1Pulmonary Department, Mainz University Hospital, Mainz, 2Department of Sleep and Respiratory Medicine, Evangelical Hospital Göttingen-Weende, Bovenden, 3Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, 4Department of Medicine, Pulmonary, and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, 5German Center for Lung Research, Marburg, 6Clinical Research Primary Care, Novartis Pharma GmbH, Nürnberg, 7Facharztforum Fürth, Fürth, Germany Introduction: Randomized interventional trials generally recruit highly selected patients. In contrast, long-term, noninterventional studies can reflect standard of care of real-life populations. DACCORD (Die ambulante Versorgung mit langwirksamen Bronchodilatatoren: COPD-Register in Deutschland [Outpatient Care With Long-Acting Bronchodilators: COPD Registry in Germany]) is an ongoing observational study, conducted in primary and secondary care in Germany, aiming to describe the impact of disease and treatments on real-life patients with chronic obstructive pulmonary disease (COPD). Methods: Patients had a clinical and spirometry diagnosis of COPD, were aged ≥40 years, and were initiating or changing COPD maintenance medication. The only exclusion criteria were asthma and participation in a randomized clinical trial. Exacerbation data were collected every 3 months. COPD medication, COPD Assessment Test, and forced expiratory volume in 1 second (FEV1) were recorded at the end of the 1 year period. Results: In the 6 months prior to baseline, 26.5% of the 3,974 patients experienced ≥1 exacerbation, compared with 26.1% over the 1-year follow-up (annualized rate 0.384). Importantly, only previous exacerbations and not poor lung function alone predicted an increased exacerbation risk. There was a general shift to lower disease severity from baseline to 1 year, predominantly as a consequence of a lower proportion of patients considered at high risk due to exacerbations. COPD Assessment Test mean change from baseline was -1.9, with 48.9% of patients reporting a clinically relevant improvement. Overall persistence to medication was high, with 77.2% of patients still receiving the same class of medication at 1 year. Conclusion: DACCORD suggests that in clinical practice, the large majority of COPD patients are symptomatic but seldom exacerbate and that widely used tools and treatment recommendations do not reflect this fully. Keywords: COPD, epidemiology, COPD exacerbationsKeywords
This publication has 29 references indexed in Scilit:
- Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialThe Lancet, 2016
- The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methodsBMC Pulmonary Medicine, 2015
- Resource Use and Costs up to Two Years Post Diagnosis Among Newly Diagnosed COPD Patients in the UK Primary Care Setting: A Retrospective Cohort StudyCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2014
- Trends in management and outcomes of COPD patients in primary care, 2000–2009: a retrospective cohort studynpj Primary Care Respiratory Medicine, 2014
- Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS)Primary Care Respiratory Journal, 2013
- Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to Evaluate Severity of COPD ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Physical Activity and Hospitalization for Exacerbation of COPDChest, 2006